Heron Therapeutics | HRTX - Selling And Administration Expenses


Heron Therapeutics reported $23.74M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
ALKERMES USD 264.59M 77.4M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
Eisai JPY 119.54B 7.82B Mar/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Esperion Therapeutics USD 39.42M 456K Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.26M 34.78M Mar/2026
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 83.88M 7.99M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Veracyte USD 50.84M 7.53M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026